Wijnands M J, Van 'T Hof M A, Van De Putte L B, Van Riel P L
Department of Rheumatology, University Hospital Nijmegen, The Netherlands.
Br J Rheumatol. 1993 Apr;32(4):313-8. doi: 10.1093/rheumatology/32.4.313.
The disease RA itself is assumed to be a risk factor for the occurrence of adverse drug reactions during sulphasalazine therapy. A meta-analysis comparing treatment termination because of toxicity among RA, inflammatory bowel disease and seronegative spondylarthropathy patients was conducted. It is shown that RA itself does not appear to predispose to treatment discontinuation because of adverse reactions. Differences found in the incidence of side effects among the various disease groups can probably be explained by patient selection, particularly with respect to age, proportion treated for the first time with sulphasalazine, and dosage used. The side effect profiles in the three groups studied are not different. However, a trend towards greater haematological and hepatic toxicity in rheumatic patients is noticed.
类风湿关节炎（RA）本身被认为是柳氮磺胺吡啶治疗期间发生药物不良反应的一个风险因素。开展了一项荟萃分析，比较类风湿关节炎、炎症性肠病和血清阴性脊柱关节病患者因毒性而终止治疗的情况。结果显示，类风湿关节炎本身似乎并不会因不良反应而导致治疗中断。不同疾病组之间副作用发生率的差异可能可以通过患者选择来解释，特别是在年龄、首次使用柳氮磺胺吡啶治疗的比例以及所用剂量方面。所研究的三组的副作用特征并无差异。然而，注意到风湿患者有血液学和肝脏毒性更大的趋势。
